GPX3 and thrombotic disease: Decreased GPX3 activity in the plasma of patients with cerebral thrombotic disorder leads to high ROS levels and rapid nitric oxide inactivation, whereas exogenous GPX3 supplementation in patients’ plasma can reverse nitric oxide-mediated platelet inhibition, offering protection against thrombotic disorder [195].